|
Unique
EQUEST is first 'single-standard dose' wormer to control
potentially lethal encysted inhibited (EL3) small redworm
 |
Market leading EQUEST
(moxidectin) has been awarded a new licence for
the control of encysted inhibited (EL3) small redworm
(cyathostomes) in the current single-standard-dose
syringe format. This means that unique EQUEST gel,
with its 13 week dosing interval, is the only wormer
licensed to provide horse owners with protection
against ALL stages of the potentially lethal small
redworms' lifecycle in a convenient single-standard-dose
treatment. The new licence is based on the work
of Ken Bairden's team at Glasgow University, Department
of Veterinary Parasitology1, 2. |
Dr Ken Bairden, Consultant Parasitologist explains,
"Our recent studies have shown that EQUEST is highly
effective against adult and larval stages of small
redworm infection, giving over 90% and up to 99.9%
reduction in EL3 and developing encysted larvae,
respectively, when compared to controls. Together
with its persistent activity profile and its activity
against benzimidazole-resistant small redworms,
this makes EQUEST the best preparation available
for the treatment of equine small redworm infection." |
Previously,
owners wishing to control the 'difficult-to-treat' encysted
inhibited (EL3) small redworm were obliged to use a
5-day course of fenbendazole. But with levels of reported
resistance to fenbendazole continuing to grow, and the
fact that selection for fenbendazole resistance has
been shown in a recent study 3 to actually increase
after only two treatments with a 5-day course of fenbendazole,
the need for a truly effective treatment for encysted
small redworm control has never been greater.
Keith
Chandler, BVMS CertEP MRCVS of the Moray Coast Veterinary
Group, reinforces these points with his comments on
resistance, "We consider that there is little benefit
in rotating a wormer from year to year. The key to preventing
resistance is to use a wormer such as EQUEST, which
is highly effective against all stages of the small
redworm lifecycle. Unlike the older wormers, EQUEST
effectively prevents small redworms from surviving so
that there are no 'next generations' capable of becoming
resistant."
Helen
Barnes, the Equine Business Unit Manager at Fort Dodge
Animal Health supports this statement, "EQUEST has always
been active against encysted small redworm, with a licence
claim against the developing encysted stage, but further
sudies, part of Fort Dodge's commitment to equine health
have provided the evidence required to attainit is only
recently that sufficient scientific evidence has been
gathered to provide the basis for the new EL3 licence
claim. So now the horse-owning public who have been
regularly using EQUEST as their routine 'four times
a year' wormer can be assured that they were also effectively
treating their horses for the most dangerous dormant
encysted inhibited (EL3) variety of small redworm."
Based
on its unique the novel moxidectin molecule, EQUEST
is now the only wormer licensed to control all stages
of encysted small redworms in a single standard dose.
The unique persistent activity of EQUEST suppresses
the re-appearance of small redworm eggs for 90 days
and prevents re-infection for two weeks after dosing.
Importantly, and in contrast to fenbendazole, there
is no known resistance to EQUEST.
References:
1 Efficacy of moxidectin 2 per cent gel against naturally
acquired strongyle infections in horses, with particular
reference to larval cyathostomes. Ken Bairden et al.
Veterinary Record (2001) 148,138-141.
2 Data on file
3. Comparison of Cyathostome Control and Selection for
Benzimidazole Resistance Using Larvicidal Regimens of
Moxidectin Gel or Fenbendazole Paste. Craig Reinemeyer,
Amy Farley, Bill Clymer. The Journal of Applied Research
in Veterinary Medicine. Vol 1, No1, Winter 2003.
|
